Reveal LINQ vs Tempus ECG-AF
AI Verdict
Choose Reveal LINQ if…
Choose Reveal LINQ if continuous, long-term monitoring is required to diagnose infrequent or transient cardiac arrhythmias that are difficult to capture with traditional methods. This implantable cardiac monitor is ideal for patients experiencing unexplained syncope, cryptogenic stroke, or suspected paroxysmal atrial fibrillation, providing up to three years of continuous ECG data.
View Reveal LINQ →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm analyzes standard 12-lead ECGs to support earlier identification and follow-up for at-risk individuals without pre-existing AF.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Reveal LINQ | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | The Reveal LINQ ICM is an implantable device placed just beneath the skin in the upper left side of the chest through a small incision. The system includes a MyCareLink™ Monitor, a bedside unit that collects data from the ICM and sends it to the doctor. The Reveal LINQ Mobile Manager app, used by healthcare professionals, is downloaded to an iPad or Android tablet and paired via Bluetooth to a Medtronic patient connector, which communicates with the ICMs. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF (Tool B) is a software solution that integrates into existing healthcare facility systems and analyzes standard 12-lead ECGs, avoiding an invasive procedure for the patient. Reveal LINQ (Tool A), while offering continuous monitoring, requires a minimally invasive surgical procedure for implantation, which presents a higher initial barrier to use for patients.
Clinical Value
Reveal LINQReveal LINQ (Tool A) provides continuous, long-term ECG monitoring for up to three years, enabling definitive detection and diagnosis of intermittent cardiac arrhythmias with AI-powered accuracy. Tempus ECG-AF (Tool B) offers a predictive AI algorithm that identifies patients at increased risk of developing AF within 12 months, which is valuable for proactive care but does not offer the direct, long-term diagnostic confirmation of actual events that Tool A provides.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly provides CMS reimbursement codes (CPT 0764T and CPT 0765T) and a Medicare rate of $128.90, offering clear financial transparency for healthcare providers. Reveal LINQ (Tool A) states that pricing is not publicly disclosed and requires direct vendor contact, making it more challenging for providers to assess its financial value upfront.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF (Tool B) is a software-only solution designed for integration into existing healthcare facility systems and is compatible with major ECG vendors like GE and Philips, simplifying deployment and ongoing management within an enterprise IT environment. Reveal LINQ (Tool A) involves managing physical implantable devices, patient monitors, and a dedicated data network, which adds logistical complexity for large organizations.
Innovation
Tempus ECG-AFTempus ECG-AF (Tool B) represents innovation by applying AI to standard 12-lead ECGs to predict the *future risk* of developing AF, shifting the paradigm from reactive diagnosis to proactive identification and preventative care. While Reveal LINQ (Tool A) innovates in device miniaturization and AI-enhanced diagnostic accuracy, the predictive capability of Tool B offers a more transformative application of AI in cardiology.
Support & Docs
Reveal LINQMedtronic (Tool A) offers extensive documentation for clinicians and patients, including detailed manuals and setup guides, along with dedicated technical and patient support lines. Tempus (Tool B) provides direct contact for support via email and phone, but the breadth and depth of publicly available, product-specific documentation appear less comprehensive compared to Medtronic's established resources for an implantable device.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Reveal LINQ | Tempus ECG-AF |
|---|---|---|
| Tool Name | Reveal LINQ | Tempus ECG-AF |
| Company | Medtronic | Tempus AI, Inc. |
| Primary Function | Continuously records ECG for up to three years, utilizing AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Target Patient Population / Use Case | Patients needing continuous ECG monitoring for cardiac arrhythmias. | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for identifying increased risk of new onset AF within 12 months. |
| Monitoring/Prediction Duration | Up to three years of continuous ECG monitoring. | Identifies risk of developing AF within the next 12 months. |
Videos
Demos, reviews, and walkthroughs featuring Reveal LINQ and Tempus ECG-AF.